News Room
| NO | Title | Date | Viewers |
|---|---|---|---|
| 60 | HanAll Biopharma Reports Full-Year 2021 Results and Provides Business Update | 2022-01-21 | 2955 |
| 59 | HanAll to Present at Korea Bio Investment Conference 2021 | 2021-12-06 | 2477 |
| 58 | HanAll Biopharma Initiates Dosing in VELOS-3, a Second Phase 3 of HL036 in Patients with Dry Eye Disease (DED) | 2021-11-24 | 3047 |
| 57 | HanAll Biopharma Reports Third Quarter 2021 Results | 2021-10-27 | 3038 |
| 56 | HanAll's Partner HBM Completes First Dosing of Phase 2 of Batoclimab in TED in China | 2021-10-20 | 2561 |
| 55 | HanAll's Partner HBM Initiates Phase 3 of Batoclimab in gMG in China | 2021-09-28 | 2297 |
| 54 | HanAll's Partner HBM Announces IND Approval for Phase 2 of Batoclimab in CIDP in China | 2021-09-02 | 2016 |
| 53 | HanAll Biopharma and Daewoong Pharmaceutical Invest $1M USD in Alloplex Biotherapeutics | 2021-08-20 | 2039 |
| 52 | HanAll Biopharma Reports Second Quarter 2021 Results | 2021-07-28 | 2574 |
| 51 | HanAll Biopharma Submits IND for Second Phase 3 (VELOS-3) of HL036 in Dry Eye Disease | 2021-07-22 | 2407 |